Roivant Sciences

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Tuesday, October 3, 2023
Slate, LLP, Prior, Sumitomo Pharma, Committee, Disclosure, Special, Proxy, Mergers and acquisitions, Skadden, Arps, Slate, Meagher & Flom, Roivant Sciences, Complaint, United Nations Special Committee on Palestine, Pomerantz

NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Lokavant Announces $8M Strategic Investment from Mitsui & Co. to Expand AI and Predictive Clinical Trial Intelligence into Asia-Pacific

Retrieved on: 
Tuesday, October 3, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Artificial Intelligence, Threat Intelligence Platform, Mitsui, Mitsui & Co., Clinical trial, Intelligence, Roivant Sciences, RWD, ChromeOS, Fine chemical, Pharmaceutical industry

Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.

Key Points: 
  • Lokavant , the clinical trial intelligence platform company, today announces an $8 million strategic investment from global business titan Mitsui & Co. Ltd. to expand its AI-optimized platform across the Asia-Pacific (APAC) region.
  • Now, with Mitsui’s support, Lokavant is poised to open a new APAC headquarters in Tokyo.
  • Mitsui’s investment in Lokavant is the culmination of a yearlong effort between the two companies, which included Mitsui’s extensive due diligence of the global clinical trials landscape.
  • Lokavant has raised a total of $29 million in funding to expand its intelligence technology for additional applications – from trial participant diversity modeling to site feasibility planning.

Immunovant Announces Closing of Upsized Common Stock Financing and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Monday, October 2, 2023
Exercise, Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock.

Key Points: 
  • This includes the exercise in full by the underwriters of their option to purchase up to 1,105,500 additional shares of common stock.
  • Concurrent with the public offering, Immunovant sold 4,473,684 shares of common stock to Roivant Sciences, Ltd. at a price of $38.00 per share in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, or the Securities Act.
  • Leerink Partners, Piper Sandler, Guggenheim Securities and Wells Fargo Securities acted as joint bookrunning managers for the public offering.
  • The shares in the public offering were offered by Immunovant pursuant to a Registration Statement on Form S-3 previously filed and declared effective by the SEC.

Immunovant Announces Pricing of $450 Million Common Stock Financing

Retrieved on: 
Thursday, September 28, 2023
Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

All of the shares are to be sold by Immunovant.

Key Points: 
  • All of the shares are to be sold by Immunovant.
  • Immunovant offered 7,370,000 shares of its common stock in the public offering, at an offering price of $38.00 per share.
  • In addition, Immunovant has granted the underwriters for the public offering a 30-day option to purchase up to an additional 1,105,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.
  • Leerink Partners, Piper Sandler, Guggenheim Securities and Wells Fargo Securities are acting as joint bookrunning managers for the public offering.

Immunovant Announces Proposed Offering of $300 Million of Common Stock

Retrieved on: 
Tuesday, September 26, 2023
Attention, Floor, SVB Securities, The 8th Floor, Telephone, Roivant Sciences, Sale, Prospectus, State Street, Wells Fargo, Form, Madison Avenue, Nicollet Mall, Guggenheim Partners, Security (finance)

Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering.

Key Points: 
  • Immunovant intends to offer and sell $130,000,000 of shares of its common stock in an underwritten public offering.
  • In addition, Immunovant intends to grant the underwriters for the offering a 30-day option to purchase up to an additional $19,500,000 of shares of its common stock offered at the public offering price.
  • Concurrent with the proposed public offering, Immunovant intends to sell $170,000,000 of shares of its common stock to Roivant Sciences Ltd. in a private placement exempt from the registration requirements of the Securities Act of 1933, as amended, subject to consummation of the proposed public offering and other customary conditions.
  • The proposed public offering and concurrent private placement are subject to market and other conditions, and there can be no assurance as to whether or when the proposed public offering and concurrent private placement may be completed, or the actual size or terms of the proposed public offering and concurrent private placement.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Myovant Sciences, Ltd. - MYOV

Retrieved on: 
Tuesday, September 26, 2023
Slate, LLP, Prior, Sumitomo Pharma, Committee, Disclosure, Special, Proxy, Mergers and acquisitions, Skadden, Arps, Slate, Meagher & Flom, Roivant Sciences, Complaint, United Nations Special Committee on Palestine, Pomerantz

NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).

Key Points: 
  • NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Myovant Sciences, Ltd. (“Myovant” or the “Company”) (NASDAQ: MYOV).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Myovant and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Wohl & Fruchter LLP Has Filed a Class Action Lawsuit on Behalf of Former Shareholders of Myovant Sciences, Ltd. in the U.S. District Court for the Southern District of New York

Retrieved on: 
Thursday, September 14, 2023
Court, District court, Security (finance), Acquisition, Bangladesh Securities and Exchange Commission, Roivant Sciences

MONSEY, N.Y., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on September 13, 2023, it filed a securities class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences, Ltd. et al., Case No.

Key Points: 
  • MONSEY, N.Y., Sept. 14, 2023 (GLOBE NEWSWIRE) -- Wohl & Fruchter LLP announces that on September 13, 2023, it filed a securities class action lawsuit in the United States District Court for the Southern District of New York (“Court”), captioned Zappia v. Myovant Sciences, Ltd. et al., Case No.
  • Investors are hereby notified that not later than 60 days after the date of this notice, any member of the purported Class may move the Court to serve as lead plaintiff of the purported Class in this action.
  • If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending action, please contact us by phone at 866-833-6245, or via email at [email protected] .
  • You may also learn more about the action and download a copy of the complaint by visiting:

Coda Octopus Group Reports Fiscal Third Quarter 2023 Financial Results

Retrieved on: 
Wednesday, September 13, 2023
NIWC, Maintenance, Partnership, United States Navy, Defense, Person, Naval Information Warfare Center Pacific, Roivant Sciences, Perception, 3D, Tax, Business, ICEX: US Navy Mission in Arctic, CODA, Wind, Tablet, Research and development, Development, Marine, Navy, Growth, UCT, Research, Commander of the Navy (Sri Lanka), YTD, ROV, Safety, Department of Defence, 3D printing, Surveying, Cryptocurrency, Security (finance), Music, Health care, Renewable energy, Video game

ORLANDO, FL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and diving technology, today reported its unaudited financial results for its fiscal third quarter ended July 31, 2023 (TQ2023) and the nine months then ended (YTD 2023).

Key Points: 
  • ORLANDO, FL, Sept. 13, 2023 (GLOBE NEWSWIRE) -- Coda Octopus Group, Inc. (“CODA” or the “Company”) (Nasdaq: CODA), a global market leader in real-time 3D/4D/5D and 6D imaging sonar technology for real-time subsea intelligence and diving technology, today reported its unaudited financial results for its fiscal third quarter ended July 31, 2023 (TQ2023) and the nine months then ended (YTD 2023).
  • Third Quarter 2023 Operational Summary:
    Management continues to focus on and execute against its core business strategy to grow the Company.
  • “As we enter the last quarter of fiscal year 2023, our priority continues to be making progress with the growth strategy.
  • CODA will host a conference call today, September 13, at 10:00 a.m. Eastern Time (7:00 a.m. Pacific Time) to discuss its results for the third fiscal quarter ended July 31, 2023.

4DMT Appoints Uneek Mehra as Chief Financial and Business Officer

Retrieved on: 
Tuesday, September 12, 2023
Acceleration, Management development, Human resources, University, IBM, Bachelor, IPO, Engineering, Chief business officer, Culture, Business, MBA, Birla Institute of Technology and Science, Pilani – Dubai Campus, International Institute for Nanotechnology, MS, Treasury, International, Novartis, CBO, Uneek Havana Cigar Company, Roivant Sciences, CFO, Growth, Citibank, Birla Institute of Technology, Mesra, Certified Treasury Professional, Management, Pharmaceutical industry, Science, Oncology, Facility, Electronics

EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.

Key Points: 
  • EMERYVILLE, Calif., Sept. 12, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, today announced the appointment of Uneek Mehra as Chief Financial & Business Officer of 4DMT.
  • Mr. Mehra will lead 4DMT’s finance, business development, and precommercial functions and will be a member of 4DMT’s Executive Team, reporting to David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • “We are thrilled to welcome Uneek to 4DMT at an important inflection point in our company progress towards pivotal trials across multiple programs,” said David Kirn, M.D., Co-founder and Chief Executive Officer of 4DMT.
  • As Chief Financial Officer of the US Integrated Care and Critical Care Business Units, Mr. Mehra supported commercial excellence across multiple products; notably, driving the launch and execution of Cosentyx® and Entresto®.

Avalyn Pharma Appoints Business Operations Leader, Melissa Rhodes, to the Role of Chief Operating Officer

Retrieved on: 
Monday, September 11, 2023
GSK plc, Duke University Hospital, Doctor of Philosophy, Pulmonary fibrosis, American Board of Commissioners for Foreign Missions, Patient, Roivant Sciences, Knowledge, Therapy, Pharmacology, Pharmaceutical industry, Toxicology

Seattle, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today announced the appointment of Melissa Rhodes, Ph.D. , D.A.B.T to the newly created position of chief operating officer (COO).

Key Points: 
  • Seattle, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc. , a clinical-stage biopharmaceutical company focused on development of targeted therapies for life-threatening pulmonary diseases, today announced the appointment of Melissa Rhodes, Ph.D. , D.A.B.T to the newly created position of chief operating officer (COO).
  • Earlier in her career, she held the position of chief development officer at Aerami Therapeutics and Altavant Sciences, both of which were focused on the delivery of inhaled medicines.
  • She holds a Ph.D. in pharmacology and toxicology from Duke University Medical Center and is a Diplomate of the American Board of Toxicology.
  • “I share Avalyn’s desire to provide an effective inhaled delivery option to patients with interstitial lung diseases.” Dr. Rhodes added.